GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CombiGene AB (OSTO:COMBI) » Definitions » EV-to-FCF

CombiGene AB (OSTO:COMBI) EV-to-FCF : 0.89 (As of Apr. 15, 2025)


View and export this data going back to 2015. Start your Free Trial

What is CombiGene AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CombiGene AB's Enterprise Value is kr-26.62 Mil. CombiGene AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-29.95 Mil. Therefore, CombiGene AB's EV-to-FCF for today is 0.89.

The historical rank and industry rank for CombiGene AB's EV-to-FCF or its related term are showing as below:

OSTO:COMBI' s EV-to-FCF Range Over the Past 10 Years
Min: -48.5   Med: -0.6   Max: 218.08
Current: 0.89

During the past 9 years, the highest EV-to-FCF of CombiGene AB was 218.08. The lowest was -48.50. And the median was -0.60.

OSTO:COMBI's EV-to-FCF is ranked better than
66.08% of 457 companies
in the Biotechnology industry
Industry Median: 2.23 vs OSTO:COMBI: 0.89

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-15), CombiGene AB's stock price is kr2.38. CombiGene AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-2.260. Therefore, CombiGene AB's PE Ratio (TTM) for today is At Loss.


CombiGene AB EV-to-FCF Historical Data

The historical data trend for CombiGene AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CombiGene AB EV-to-FCF Chart

CombiGene AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -2.82 4.05 -2.96 1.57 0.89

CombiGene AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 0.65 0.82 0.69 0.89

Competitive Comparison of CombiGene AB's EV-to-FCF

For the Biotechnology subindustry, CombiGene AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CombiGene AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CombiGene AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CombiGene AB's EV-to-FCF falls into.


;
;

CombiGene AB EV-to-FCF Calculation

CombiGene AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-26.621/-29.949
=0.89

CombiGene AB's current Enterprise Value is kr-26.62 Mil.
CombiGene AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-29.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CombiGene AB  (OSTO:COMBI) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CombiGene AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.38/-2.260
=At Loss

CombiGene AB's share price for today is kr2.38.
CombiGene AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-2.260.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CombiGene AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CombiGene AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CombiGene AB Business Description

Traded in Other Exchanges
N/A
Address
Agavagen 52A, Lidingo, SWE, SE-181 55
CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present. It develops gene therapies with the ambition to offer patients affected by severe life-changing diseases opportunities for a better life.

CombiGene AB Headlines

No Headlines